Harrow Health - רווח נקי למניה אחת בשנים עשר החודשים האחרונים HROW

Harrow, Inc. dominates the production of ophthalmic drops, minimizing regulatory risks through a broad brand portfolio. This annual EPS TTM chart confirms this success, with the metric settling at -434.30. Revenues are based on the supply of steroids and analgesics to clinics, while expansion into the affordable generics segment allows the company to effectively displace traditional medication suppliers.
HROW (Harrow, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Harrow, Inc. (HROW) leverages an effective ophthalmology asset consolidation strategy and management M&A expertise to directly scale net income. By analyzing year-over-year EPS (TTM) comparisons, investors can assess earnings per share growth rates over a rolling year, allowing them to filter out market volatility and confirm the fundamental stability of the stock price without the risk of overpaying.